Delayed diagnosis of multiple sclerosis in a low prevalence country

Cárdenas‐Robledo, Simón; López-Reyes, Lorena; Arenas-Vargas, Laura Estefanía; Carvajal, Michael; Guío-Sánchez, Claudia

doi:10.1080/01616412.2020.1866374

Cited by 14 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no differences between both groups regarding the first speciality sought, previous misdiagnosis, frequency of relapses or the current EDSS scores. These findings regarding the difference between gender were in line with the previous reports 6 , 14 , 16 , 19 , 26 . In contrast to the study from Iran, patient delay in seeking medical advice was noted in men compared to women 18 .…”

Section: Discussionsupporting

confidence: 93%

“…As was evident in the current study, the number of patients with a delayed diagnosis has decreased over time, and the time to diagnosis has shortened significantly. Also, presentation in earlier periods was an independent predictor for the diagnostic delay, in concordance with previous findings [13][14][15][16] . A possible explanation might be the increased awareness of the neurological symptoms among the public, alongside the updated MS diagnostic criteria over the years, making it easier to confirm the diagnosis earlier.…”

Section: Discussionsupporting

confidence: 91%

“…In contrast, In Portuguese, older age at onset was associated with a longer time to diagnosis, which was primarily explained by a broader age-related differential diagnosis of MS 12 . In Colombia, no link was found between age at onset and delayed diagnosis 16 . These differences between studies could be also attributed to differences in MS prevalence, differences in MS risk factors leading to the variability of the age at onset in different countries, or even different paths of access to the diagnostic facilities 18 .…”

Section: Discussionmentioning

confidence: 94%

“…In another study from Spain, the mean age of patients at the onset of the disease was 31.2 years 15 . In Colombia, the mean age at the time of the first symptom was 32.4 ± 10.6 years, and at the time of diagnosis was 34.5 ± 10.5 years 16 . On the other hand, women had a typical representation in our cohort (72.5%), following the known global epidemiology of MS and the MENA area, with a female–to–male ratio of 2.6:1 4 .…”

Section: Discussionmentioning

confidence: 99%

“…In the study by Fernandez et al 15 , the delay was 24.9 months. In Colombia, the overall mean diagnostic delay was 3.07 years (SD 3.83), and about 45.7% of the patients had a delayed diagnosis 16 . The possible reasons for the observed variations between countries are the different levels of health literacy among different populations, different ways the referral processes work, the strength and Regarding age, in the current study, we found a statistically significant difference between the two groups regarding the age at onset (p = 0.041), where the diagnostic delay was more common at a younger age of onset.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients

Khedr

Malky

Hussein

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The earlier the diagnosis of multiple sclerosis (MS), the sooner disease-modifying treatments can be initiated. However, significant delays still occur in developing countries. We aimed to identify factors leading to delayed diagnosis of MS in Upper Egypt. One hundred forty-two patients with remitting relapsing MS (RRMS) were recruited from 3 MS units in Upper Egypt. Detailed demographic and clinical data were collected. Neurological examination and assessment of the Disability Status Scale (EDSS) were performed. The mean age was 33.52 ± 8.96 years with 72.5% of patients were females. The mean time from symptom onset to diagnosis was 18.63 ± 27.87 months and the median was 3 months. Seventy-two patients (50.7%) achieved diagnosis within three months after the first presenting symptom (early diagnosis), while seventy patients (49.3%) had more than three months delay in diagnosis (delayed diagnosis). Patients with a delayed diagnosis frequently presented in the period before 2019 and had a significantly higher rate of initial non-motor presentation, initial non-neurological consultations, prior misdiagnoses, and a higher relapse rate. Another possible factor was delayed MRI acquisition following the initial presentation in sixty-six (46.5%) patients. Multivariable logistic regression analysis demonstrated that earlier presentation, initial non-neurological consultation, and prior misdiagnosis were independent predictors of diagnostic delay. Despite advances in MS management in Egypt, initial non-neurological consultation and previous misdiagnoses are significant factors responsible for delayed diagnosis in Upper Egypt.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients

Khedr

Malky

Hussein

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Niu

Zhao

et al. 2023

Small

View full text Add to dashboard Cite

Neurological diseases are the foremost cause of disability and the second leading cause of death worldwide. Owing to the special microenvironment of neural tissues and biological characteristics of neural cells, a considerable number of neurological disorders are currently incurable. In the past few years, the development of nanoplatforms based on metal–organic frameworks (MOFs) has broadened opportunities for offering sensitive diagnosis/monitoring and effective therapy of neurology‐related diseases. In this article, the obstacles for neurotherapeutics, including delayed diagnosis and misdiagnosis, the existence of blood brain barrier (BBB), off‐target treatment, irrepressible inflammatory storm/oxidative stress, and irreversible nerve cell death are summarized. Correspondingly, MOFs‐based diagnostic/monitoring strategies such as neuroimaging and biosensors (electrochemistry, fluorometry, colorimetry, electrochemiluminescence, etc.) and MOFs‐based therapeutic strategies including higher BBB permeability, targeting specific lesion sites, attenuation of neuroinflammation/oxidative stress as well as regeneration of nerve cells, are extensively highlighted for the management of neurological diseases. Finally, the challenges of the present research from perspective of clinical translation are discussed, hoping to facilitate interdisciplinary studies at the intersections between MOFs‐based nanoplatforms and neurotheranostics.

show abstract

Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study

Khodaie,

Moghadasi,

Hosseinnataj

et al. 2024

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Delayed diagnosis of multiple sclerosis in a low prevalence country

Cited by 14 publications

References 32 publications

Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients

Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study

Contact Info

Product

Resources

About